TWTakafumi Wada

Takafumi Wada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takafumi Wada has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acute inhibition of AMPA receptors by perampanel reduces amyloid β‐protein levels by suppressing β‐cleavage of APP in Alzheimer's disease models

    by Sakiho Ueda, Akira Kuzuya, Masayoshi Kawata, Kohei Okawa, Chika Honjo, Takafumi Wada, Mizuki Matsumoto, Kazuya Goto, Masakazu Miyamoto, Atsushi Yonezawa, et al.

    Hippocampal hyperexcitability is a promising therapeutic target to prevent Aβ deposition in AD since enhanced neuronal activity promotes presynaptic Aβ production and release. This article highlights the potential application of perampanel (PER), an AMPA receptor (AMPAR) antagonist approved for partial seizures, as a therapeutic agent for AD. Using transgenic AD mice combined with in vivo brain microdialysis and primary neurons under oligomeric Aβ‐evoked neuronal hyperexcitability, the acute effects of PER on Aβ metabolism were investigated. A single oral administration of PER rapidly decreased ISF Aβ 40 and Aβ 42 levels in the hippocampus of J20, APP transgenic mice, without affecting the Aβ 40 /Aβ 42 ratio; 5 mg/kg PER resulted in declines of 20% and 31%, respectively. Moreover, PER‐treated J20 manifested a marked decrease in hippocampal APP βCTF levels with increased FL‐APP levels. Consistently, acute treatment of PER reduced sAPPβ levels, a direct byproduct of β‐cleavage of APP, released to the medium in primary neuronal cultures under oligomeric Aβ‐induced neuronal hyperexcitability. To further evaluate the effect of PER on ISF Aβ clearance, a γ‐secretase inhibitor was administered to J20 1 h after PER treatment. PER did not influence the elimination of ISF Aβ, indicating that the acute effect of PER is predominantly on Aβ production. In conclusion, acute treatment of PER reduces Aβ production by suppressing β‐cleavage of amyloid‐β precursor protein effectively, indicating a potential effect of PER against Aβ pathology in AD.


  • Open Access

    Punctate Enhancement of Bilateral Basal Ganglia in a Case of Epstein-Barr Virus Encephalitis

    by Takafumi Wada, Toru Yamamoto, Akihiko Ozaki

    Epstein-Barr virus (EBV) encephalitis is caused by initial infection or reactivation of EBV. In adults, the risk factors of EBV encephalitis include human immunodeficiency virus infection, immunosuppressant drugs, congenital immune deficiencies, post-stem cell transplantation, and post-solid organ transplantation. However, a few cases of adult-onset EBV encephalitis without these risk factors were also reported. The efficacy of steroid or intravenous immunoglobulin remains unclear in the treatment of EBV encephalitis. Herein, we report a case of an 82-year-old man with fever and disturbance of consciousness who was diagnosed as having EBV encephalitis. Gadolinium-enhanced magnetic resonance imaging showed punctate enhancement in the bilateral basal ganglia, which resembled chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Symptoms and enhanced lesions improved after immunotherapy. Immunotherapy may be effective in the treatment of EBV encephalitis with CLIPPERS-like lesions.


  • An autopsy case of adult‐onset neuronal intranuclear inclusion disease with perivascular preservation in cerebral white matter

    by Daisuke Yoshii, Takashi Ayaki, Takafumi Wada, Akihiko Ozaki, Toru Yamamoto, Yoshimi Miyagi, Hideto Senzaki, Ryosuke Takahashi

    Neuronal intranuclear inclusion disease (NIID) is a neurodegenerative disease characterized by appearance of eosinophilic hyaline intranuclear inclusions. While the main symptoms of adult‐onset NIID are dementia or limb weakness, some patients present with encephalitic episodes and transient neurological symptoms. The pathophysiology of these acute, transient symptoms, however, remains unknown. Here, we describe an autopsy case of adult‐onset NIID with progressive dementia and transient hemiparesis. The patient was a 70‐year‐old man without a relevant family history, and initially presented with progressive dementia. He then exhibited transient left hemiparesis at 75 years of age and died of ureteral cancer at 77 years of age. Neuropathological examination revealed the presence of multiple areas of focal spongiosis in the subcortical white matter and patchy myelin pallor of the white matter, as in previous reports. However, perivascular areas were preserved even in the damaged white matter. In addition, dense glial fibrillary acidic protein (GFAP)‐immunoreactive astrocytic processes were observed in these areas. [Correction added on 23 January 2022, after first online publication: the preceding sentence has been corrected to improve readability.] GFAP immunohistochemistry revealed decreased density and morphological abnormalities of astrocytes in the affected white matter. These pathological findings might reflect blood–brain barrier impairment and dysregulation of blood flow, which may be related to the pathophysiology of the acute, transient symptoms observed in NIID.